Latest Bisphosphonates Stories
Bernstein Liebhard LLP reports on a new discovery order issued in the federal Merck Fosamax litigation, establishing protocols for the production of documents related to Fosamax femur fractures.
Bernstein Liebhard LLP reports on a letter signed by 41 attorneys general supporting a new bill that would lift certain restrictions on the right to sue generic drug manufacturers, allowing individuals
Ennis & Ennis, PA Summarizes the Latest Fosamax Study that Confirms Long-Term Use of Biphosphonates, such as Fosamax and Boniva, Causes Atypical Femur Fractures (PRWEB)
Bernstein Liebhard LLP reports on a new study that found an increased risk of atypical femur fractures in people who take Fosamax. New York, New York (PRWEB)
Bernstein Liebhard LLP reports on a study, which found that the FDA approved more new drugs quicker than health regulatory agencies in Europe and Canada. New
New research shows when it comes to bone-cancer-related fractures, pain can be reduced by drug treatment, but no one drug is superior.
Bone cancer-related fractures and pain can be reduced by drug treatment, but no one drug is superior.
Ennis & Ennis P.A.
A new analysis of popular bone-building drugs by the US Food and Drug Administration (FDA) could prompt millions of women to rethink their use of such drugs, even though the agency fell short of issuing specific recommendations.
The Food and Drug Administration (FDA) announced today that physicians should reassess patients with osteoporosis who are being treated with a class of drugs called bisphosphonates after three to five years of therapy to determine whether they should continue treatment.
- The horn of a unicorn considered as a medical or pharmacological ingredient.
- A winged horse with a single horn on its head; a winged unicorn.